- Home
- CGO vs NTHI Comparison
CGO vs NTHI Comparison
Compare CGO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | NTHI |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.2M | 114.6M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | CGO | NTHI |
|---|---|---|
| Price | $12.97 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 29.4K | ★ 88.7K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $3.52 |
| 52 Week High | $14.20 | $12.99 |
Technical Indicators
Market Signals| Indicator | CGO | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 24.94 |
| Support Level | $12.97 | N/A |
| Resistance Level | $13.88 | $5.78 |
| Average True Range (ATR) | 0.29 | 0.34 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 1.25 | 17.63 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.